Oncogenic Mutations and Tumor Microenvironment Alterations in Diffuse Large B‐Cell Lymphoma With Bulky Disease
Open Access
- 6 September 2026
- journal article
- Published by Wiley in Cancer Medicine
- Vol. 15 (9)
Abstract
Background: Bulky disease represents a clinically aggressive subset of diffuse large B‐cell lymphoma (DLBCL) associated with adverse clinical outcomes. The aim of this study was to investigate the influence of oncogenic mutations and tumor microenvironment alterations on bulky disease in DLBCL. Methods: We analyzed a cohort of 939 patients with newly diagnosed DLBCL. Using DNA ( n = 934) and RNA ( n = 524) sequencing, we compared oncogenic mutations and tumor microenvironment (TME) alterations based on tumor diameter, with cutoff values at 5.0 cm and 10.0 cm. Further stratification by mutations in key genes (CD58, STAT6, EBF1) correlated with tumor diameter revealed distinct transcriptomic and immunologic profiles. Subsequent single‐cell RNA sequencing, guided by these mutational signatures, resolved the cellular heterogeneity within the TME. Results: Integrative analysis revealed that tumor diameter correlated with increased incidence of mutations in CD58 , STAT6 , and EBF1 ; adverse genetic subtypes such as EZB‐like MYC + and TP53 Mut ; activation of oncogenic pathways (JAK/STAT, BCR, PI3K, and MYC); and an immunosuppressive tumor microenvironment. Notably, immune checkpoint molecules varied across the bulky stages, with CTLA‐4 , TIGIT , ICOS , and CD28 expression inversely correlated with tumor diameter, while CD70 and 4‐1BBL expression positively correlated. Single‐cell RNA sequencing further revealed mutation‐specific tumor microenvironment insights. CD58 ‐mutated tumor exhibited a profoundly immune‐deserted microenvironment dominated by malignant B cells with minimal immune infiltration, whereas STAT6‐ mutated tumor was associated with increased fibroblasts and CD4 + T cells, particularly regulatory T cells (Treg) and Th1‐like cells; EBF1 ‐mutated tumor was characterized by increased proportions of malignant B cells. Conclusions: Collectively, our findings highlight the biological complexity of bulky disease, identifying candidate molecular targets and providing a biological framework for future therapeutic hypothesis generation in this clinically aggressive subset of DLBCL.Keywords
Funding Information
- National Key Research and Development Program of China (2022YFC2502600)
- National Natural Science Foundation of China (82130004)
- National Natural Science Foundation of China (82070204)
- National Natural Science Foundation of China (82200201)
- National Natural Science Foundation of China (82370187)
This publication has 42 references indexed in Scilit:
- A Mitochondria‐Related Signature in Diffuse Large B‐Cell Lymphoma: Prognosis, Immune and Therapeutic FeaturesCancer Medicine, 2025
- Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trialCancer Cell, 2023
- The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunityCancer Cell, 2023
- Comprehensive analysis of TP53 mutation characteristics and identification of patients with inferior prognosis and enhanced immune escape in diffuse large B‐cell lymphomaAmerican Journal of Hematology, 2021
- Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B‐cell lymphomaClinical and Translational Medicine, 2020
- A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic ImplicationsCancer Cell, 2020
- DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest NeighborsCell Systems, 2019
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer ProgressionCell, 2015
- Hypoxia-Inducible Factors in Physiology and MedicineCell, 2012
- Early B Cell Factor 1 Regulates B Cell Gene Networks by Activation, Repression, and Transcription- Independent Poising of ChromatinImmunity, 2010